Iga Nephropathy
Data readoutStock, pipeline and biotech catalyst intelligence
Clinical portfolio
| Asset | Indication | Stage | Milestone | Signals ? |
|---|---|---|---|---|
| Budoprutug | Kidney disease, Primary Membranous Nephropathy | Phase 2 | Dec 31, 2026 | Big moverMgmt interestHedge fund avoid |
| Budoprutug (CD19 Antibody) | Immune Thrombocytopenia | Phase 1/2 | Dec 31, 2026 | — |
| Budoprutug (CD19 Antibody) | Systemic Lupus Erythematosus | Phase 1b | Dec 31, 2026 | Mgmt interest |
Upcoming milestones
Company profile
Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies to address unmet needs for patients living with immune-mediated diseases. The company's lead product candidate is the budoprutug, an anti-CD19 monoclonal antibody for the treatment of B-cell mediated diseases. It is also developing budoprutug which is in phase 2 clinical trials for the treatment of primary membranous nephropathy and immune thrombocytopenia; and Phase 1b clinical trial indicated for the systemic lupus erythematosus. In addition, the company is developing CLYM116, a preclinical stage anti A Proliferation-inducing Ligand (APRIL) monoclonal antibody for the treatment of immunoglobin A nephropathy (IgAN) and other B-cell mediated diseases. The company was formerly known as Eliem Therapeutics, Inc. and changed its name to Climb Bio, Inc. in October 2024. Climb Bio, Inc. was incorporated in 2018 and is headquartered in Wellesley Hills, Massachusetts.
Company profile supplied by Yahoo Finance. Catalyst dates can change and should be confirmed against the linked primary source.
Page updated Aug 21, 2026 · Yahoo quotes cached for one minute; reference data may be used when a live field is unavailable.
Iga Nephropathy
Data readoutKidney disease, Primary Membranous Nephropathy
Data readout